X0609 4 2026-06-12 0000907654 Oruka Therapeutics, Inc. ORKA 0002033974 Agarwal Arjun false C/O ORUKA THERAPEUTICS, INC. 855 OAK GROVE AVE., SUITE 100 MENLO PARK CA 94025 0 1 0 0 Senior Vice President, Finance 1 Common Stock 2026-06-12 4 M 0 8000 12.5 A 25294 D Common Stock 2026-06-12 4 M 0 1459 34.39 A 26753 D Common Stock 2026-06-12 4 S 0 1859 68.3419 D 24894 D Common Stock 2026-06-12 4 S 0 4340 69.8512 D 20554 D Common Stock 2026-06-12 4 S 0 3260 70.3392 D 17294 D Common Stock 2026-06-15 4 S 0 395 69.69 D 16899 D Employee Stock Option (right to buy) 12.5 2026-06-12 4 M 0 8000 0 D 2035-01-21 Common Stock 8000 110000 D Employee Stock Option (right to buy) 34.39 2026-06-12 4 M 0 1459 0 D 2036-01-22 Common Stock 1459 62708 D Includes 888 shares acquired under the Oruka Therapeutics, Inc. stock purchase plan on June 8, 2026. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.87 to $68.71, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.07 to $70.06, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.07 to $70.86, inclusive. The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. /s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal 2026-06-15